171 related articles for article (PubMed ID: 34862329)
1. A circadian rhythm-related gene signature associated with tumor immunity, cisplatin efficacy, and prognosis in bladder cancer.
Zhou R; Chen X; Liang J; Chen Q; Tian H; Yang C; Liu C
Aging (Albany NY); 2021 Dec; 13(23):25153-25179. PubMed ID: 34862329
[TBL] [Abstract][Full Text] [Related]
2. An Immunosenescence-Related Gene Signature to Evaluate the Prognosis, Immunotherapeutic Response, and Cisplatin Sensitivity of Bladder Cancer.
Zhou R; Liang J; Tian H; Chen Q; Yang C; Liu C
Dis Markers; 2022; 2022():2143892. PubMed ID: 35280438
[TBL] [Abstract][Full Text] [Related]
3. Four circadian rhythm-related genes predict incidence and prognosis in hepatocellular carcinoma.
Wu Z; Hu H; Zhang Q; Wang T; Li H; Qin Y; Ai X; Yi W; Wei X; Gao W; Ouyang C
Front Oncol; 2022; 12():937403. PubMed ID: 36439444
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
5. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer.
Wang Y; Chen L; Yu M; Fang Y; Qian K; Wang G; Ju L; Xiao Y; Wang X
Cancer Med; 2020 Oct; 9(20):7729-7741. PubMed ID: 32841548
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes.
Wang L; Wang Y; Wang J; Li L; Bi J
J Immunol Res; 2021; 2021():3236384. PubMed ID: 34708131
[TBL] [Abstract][Full Text] [Related]
7. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
8. Development of a Ferroptosis-Related lncRNA Signature to Predict the Prognosis and Immune Landscape of Bladder Cancer.
Zhou R; Liang J; Tian H; Chen Q; Yang C; Liu C
Dis Markers; 2021; 2021():1031906. PubMed ID: 34239619
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis.
Liu L; Hu J; Wang Y; Sun T; Zhou X; Li X; Ma F
Aging (Albany NY); 2020 Jun; 12(12):11967-11989. PubMed ID: 32570217
[TBL] [Abstract][Full Text] [Related]
10. Metabolic-associated signature and hub genes associated with immune microenvironment and prognosis in bladder cancer.
Guo Y; Zheng Z; Mao S; Yang F; Wang R; Wang H; Liu J; Li C; Wang Q; Zhang W; Yao X; Liu S
Mol Carcinog; 2023 Feb; 62(2):185-199. PubMed ID: 36250643
[TBL] [Abstract][Full Text] [Related]
11. A circadian rhythm-related gene signature for predicting relapse risk and immunotherapeutic effect in prostate adenocarcinoma.
Liu J; Tan Z; Yang S; Song X; Li W
Aging (Albany NY); 2022 Sep; 14(17):7170-7185. PubMed ID: 36103249
[TBL] [Abstract][Full Text] [Related]
12. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer.
Zhang Z; Yu Y; Li P; Wang M; Jiao W; Liang Y; Niu H
Front Immunol; 2022; 13():954616. PubMed ID: 35958586
[TBL] [Abstract][Full Text] [Related]
14. Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer.
Song Y; Jin D; Chen J; Luo Z; Chen G; Yang Y; Liu X
Aging (Albany NY); 2020 Jun; 12(12):12051-12073. PubMed ID: 32579540
[TBL] [Abstract][Full Text] [Related]
15. A prognostic signature based on immune-related genes for cervical squamous cell carcinoma and endocervical adenocarcinoma.
Liu J; Wu Z; Wang Y; Nie S; Sun R; Yang J; Cheng W
Int Immunopharmacol; 2020 Nov; 88():106884. PubMed ID: 32795900
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a prognostic model to predict chemotherapy response and identification of RAC3 as a chemotherapeutic target in bladder cancer.
Chen Y; Huang M; Lu J; Zhang Q; Wu J; Peng S; Chen S; Zhang Y; Cheng L; Lin T; Chen X; Huang J
Environ Toxicol; 2024 Feb; 39(2):509-528. PubMed ID: 37310098
[TBL] [Abstract][Full Text] [Related]
17. Development and experimental validation of a folate metabolism-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
Liu X; Chen C; Xu P; Chen B; Xu A; Liu C
Funct Integr Genomics; 2023 Sep; 23(4):291. PubMed ID: 37676513
[TBL] [Abstract][Full Text] [Related]
18. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
19. Construction and validation of a metabolism-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer.
Shen C; Bi Y; Chai W; Zhang Z; Yang S; Liu Y; Wu Z; Peng F; Fan Z; Hu H
BMC Med Genomics; 2023 Oct; 16(1):264. PubMed ID: 37880682
[TBL] [Abstract][Full Text] [Related]
20. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
